

Bissan Al-Lazikani

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8792663/bissan-al-lazikani-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42 papers	8,172 citations	22 h-index	62 g-index
62 ext. papers	9,715 ext. citations	20.5 avg, IF	6.03 L-index

#	Paper	IF	Citations
42	PDBe-KB: collaboratively defining the biological context of structural data. <i>Nucleic Acids Research</i> , 2021 ,	20.1	7
41	Evolution of kinase polypharmacology across HSP90 drug discovery. <i>Cell Chemical Biology</i> , 2021 , 28, 1438-1445.e3	14.5	3
40	canSAR: update to the cancer translational research and drug discovery knowledgebase. <i>Nucleic Acids Research</i> , 2021 , 49, D1074-D1082	20.1	21
39	Tuning Local Hydration Enables a Deeper Understanding of Protein-Ligand Binding: The PP1-Src Kinase Case. <i>Journal of Physical Chemistry Letters</i> , 2021 , 12, 49-58	6.4	3
38	Public resources for chemical probes: the journey so far and the road ahead. <i>Future Medicinal Chemistry</i> , 2021 , 13, 731-747	4.1	9
37	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. <i>Cancer Research</i> , 2021 , 81, 1087-1100	10.1	5
36	The kinase polypharmacology landscape of clinical PARP inhibitors. <i>Scientific Reports</i> , 2020 , 10, 2585	4.9	32
35	Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches. <i>Scientific Reports</i> , 2020 , 10, 16000	4.9	4
34	PDBe-KB: a community-driven resource for structural and functional annotations. <i>Nucleic Acids Research</i> , 2020 , 48, D344-D353	20.1	50
33	Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. <i>Oncogene</i> , 2019 , 38, 5905-5920	9.2	13
32	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in -Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1396-1404	6.1	8
31	canSAR: update to the cancer translational research and drug discovery knowledgebase. <i>Nucleic Acids Research</i> , 2019 , 47, D917-D922	20.1	29
30	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018 , 50, 682-692	36.3	112
29	Objective, Quantitative, Data-Driven Assessment of Chemical Probes. <i>Cell Chemical Biology</i> , 2018 , 25, 194-205.e5	8.2	42
28	Leveraging Human Genetics to Guide Cancer Drug Development. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-11	5.2	1
27	Genomics, bio specimens, and other biological data: Current status and future directions. <i>Medical Physics</i> , 2018 , 45, e829-e833	4.4	2
26	Rational design of non-resistant targeted cancer therapies. <i>Scientific Reports</i> , 2017 , 7, 46632	4.9	9

25	A comprehensive map of molecular drug targets. <i>Nature Reviews Drug Discovery</i> , 2017 , 16, 19-34	64.1	1032
24	SiGNet: A signaling network data simulator to enable signaling network inference. <i>PLoS ONE</i> , 2017 , 12, e0177701	3.7	5
23	Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. <i>ELife</i> , 2017 , 6,	8.9	23
22	Polypharmacology in Precision Oncology: Current Applications and Future Prospects. <i>Current Pharmaceutical Design</i> , 2016 , 22, 6935-6945	3.3	42
21	Drug discovery in advanced prostate cancer: translating biology into therapy. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 699-718	64.1	77
20	canSAR: an updated cancer research and drug discovery knowledgebase. <i>Nucleic Acids Research</i> , 2016 , 44, D938-43	20.1	67
19	Blocking the survival of the nastiest by HSP90 inhibition. <i>Oncotarget</i> , 2016 , 7, 3658-61	3.3	10
18	Therapeutic opportunities within the DNA damage response. <i>Nature Reviews Cancer</i> , 2015 , 15, 166-80	31.3	329
17	Distinctive Behaviors of Druggable Proteins in Cellular Networks. <i>PLoS Computational Biology</i> , 2015 , 11, e1004597	5	30
16	canSAR: updated cancer research and drug discovery knowledgebase. <i>Nucleic Acids Research</i> , 2014 , 42, D1040-7	20.1	57
15	Drugging cancer genomes. <i>Nature Reviews Drug Discovery</i> , 2013 , 12, 889-90	64.1	42
14	Objective assessment of cancer genes for drug discovery. <i>Nature Reviews Drug Discovery</i> , 2013 , 12, 35-50	64.1	89
13	A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2013 , 49, 2512-21	7.5	11
12	Unpicking the combination lock for mutant BRAF and RAS melanomas. <i>Cancer Discovery</i> , 2013 , 3, 14-9	24.4	6
11	Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. <i>Current Opinion in Pharmacology</i> , 2013 , 13, 486-96	5.1	44
10	Shouldn't enantiomeric purity be included in the minimum information about a bioactive entity? Response from the MIABE group. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 730-730	64.1	
9	ChEMBL: a large-scale bioactivity database for drug discovery. <i>Nucleic Acids Research</i> , 2012 , 40, D1100-7	20.1	2257
8	Combinatorial drug therapy for cancer in the post-genomic era. <i>Nature Biotechnology</i> , 2012 , 30, 679-92	44.5	670

7	Personalized medicine: patient-predictive panel power. <i>Cancer Cell</i> , 2012 , 21, 455-8	24.3	14
6	canSAR: an integrated cancer public translational research and drug discovery resource. <i>Nucleic Acids Research</i> , 2012 , 40, D947-56	20.1	50
5	Minimum information about a bioactive entity (MIABE). <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 661-9	64.1	69
4	Genomic-scale prioritization of drug targets: the TDR Targets database. <i>Nature Reviews Drug Discovery</i> , 2008 , 7, 900-7	64.1	244
3	How many drug targets are there?. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 993-6	64.1	2624
2	The Molecular Basis of Predicting Druggability1315-1334		3
1	Coronavirus canSAR 1.3: Data-Driven, AI-Enabled, Drug Discovery Resource for the Research Community		2